Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System
Case Reports in Hematology · 2026-01 · 2026 (1)
DOI: 10.1155/crh/4126471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Hematology, online erschienen am 17.08.2026. Verfasst von Maria D'Amato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Via Roma, 67, Pisa, Italy, unipi.it. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Pisa.
Abstract (Originalsprache)
Introduction
Central nervous system (CNS) and extralymphatic involvement in chronic lymphocytic leukemia (CLL) is rare and associated with poor prognosis. Case Description We report the case of a 45‐year‐old woman with refractory CLL who developed CNS and extralymphatic lesions after three prior lines of therapy, including rituximab–bendamustine, rituximab–idelalisib, and rituximab–venetoclax. Third‐line treatment with rituximab–venetoclax led to partial remission (PR), followed by a 2‐month treatment‐free interval before the emergence of a new lesion. Treatment with zanubrutinib, a second‐generation Bruton’s tyrosine kinase inhibitor (BTKi), was initiated, resulting in significant clinical improvement and near‐complete resolution of lesions.
Discussion
Zanubrutinib’s enhanced blood–brain barrier (BBB) penetration and favorable safety profile make it a promising option for CNS–CLL and also for other extralymphatic lesions.
Conclusion
This case underscores the potential of zanubrutinib in addressing challenging CLL presentations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Via Roma, 67, Pisa, Italy, unipi.it.
- ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy, ospedaleniguarda.it.
- Department of Laboratory Medicine and Pathology, Pathology Unit, Cisanello Hospital AOUP, Via Paradisa, 2, Pisa, Italy.
ORCID-Profile: Maria D'Amato, Sara Galimberti
Förderung
- Università di Pisa
Zitieren
APA
D'Amato, M., Baratè, C., Cervetti, G., Caparello, M., Ortenzi, V., Naccarato, A. G., Benedetti, E., & Galimberti, S. (2026). Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/4126471
Vancouver
D'Amato M, Baratè C, Cervetti G, Caparello M, Ortenzi V, Naccarato AG, et al. Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/4126471
BibTeX
@article{DAmato2026,
author = {D'Amato, Maria and Baratè, Claudia and Cervetti, Giulia and Caparello, Mariacostanza and Ortenzi, Valerio and Naccarato, Antonio Giuseppe and Benedetti, Edoardo and Galimberti, Sara},
title = {Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System},
journal = {Case Reports in Hematology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crh/4126471}
}
EUVIMED